Cerluten®
Biologically active food supplement CERLUTEN® contains a complex of low molecular weight peptides
with a molecular weight of up to 5000 Da, isolated from the brain tissue of young animals - calves up
to 12 months of age or pigs.
CERLUTEN® is available in capsule form with an active ingredient content of 10 mg.
CERLUTEN® peptides regulate metabolic processes in brain cells, increase the brain’s reserve capac-
ity, have a beneficial effect on the adaptation processes of the body in extreme conditions, have an-
tioxidant properties, and regulate the processes of peroxidation in the cerebral cortex. Experimental
studies have shown that peptides have a tissue-specific effect on the cells of those tissues from which
they are isolated. This allows us to assume the effectiveness of the use of CERLUTEN® to restore the
functions of the central nervous system in case of disorders of various origins.
Treatment of diseases of the central nervous system is of particular relevance since they entail a vio-
lation of social adaptation and disability of patients (2).
Currently, in the treatment of patients with diseases of the central nervous system, taking into account
the pathogenetic mechanisms, the following traditional therapeutic agents of various directions of
action are mainly used (1, 3):
- Influence on metabolism and integrative functions of the brain - cerebrolysin, piracetam, encepha-
lolysate;
- Normalization of cerebral and systemic circulation - stugeron, cavinton;
- Relief of psychopathological manifestations - meridin, amitriptyline;
- Correction of changes in the bioelectric activity of the brain - phenobarbital, Konvulex;
- Impact on liquorodynamic disturbances - veroshpiron, furosemide;
- Prevention and inhibition of the development of adhesions - aloe, lidase;
- Correction of immunopathological reactions - levamisole, tavegil.
Clinical trials of CERLUTEN® were carried out in the period from October 2005 to February 2006 at
the Medical Center of the St. Petersburg Institute of Bioregulation and Gerontology, SZO RAMS, in
48 patients with various diseases of the central nervous system: long-term consequences of traumatic
brain injury (the duration of the trauma was from 1 to 10 years), conditions after a stroke, vascular en-
cephalopathy, and decreased mental performance, memory, and attention. In addition to conventional
drugs, patients of the primary group received CERLUTEN® 1-2 capsules 2-3 times a day before meals
for 10-20 days, depending on the severity of the pathological process. The distribution of patients by
nosological forms, sex, and age is shown in Table 1.
The control group consisted of 37 similar patients who received only conventional treatment.
All patients had previously received drugs of symptomatic and pathogenetic action, with the use of
which a short-term therapeutic effect was noted, requiring an increase in the dose of drugs for the
course of treatment and their prolonged use.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.